Quality Control and Impurity Research Progress of Eicosapentaenoic Acid Ethyl Ester (EPA-EE) (With CATO's Full List of Impurity Reference Standards)
Eicosapentaenoic acid ethyl ester (EPA-EE), also known as EPA ethyl ester, is an omega-3 fatty acid derivative derived from eicosapentaenoic acid (EPA). Through multiple mechanisms such as inhibiting the production of inflammatory mediators, improving blood lipid profiles, and stabilizing plaques, EPA-EE has demonstrated broad application value in anti-inflammatory, cardiovascular and cerebrovascular health care, and mental health promotion.
Structural formula of eicosapentaenoic acid
Since 1990, EPA-EE has been gradually recognized worldwide. It was initially launched by Japan's Mochida Pharmaceutical Co., Ltd., and in 2012, Amarin's Vascepa (trade name) was approved by the US FDA. These products marked the breakthrough application of EPA-EE in the treatment of cardiovascular disease. In particular, Vascepa, as a prescription drug for reducing the risk of atherosclerotic disease, occupies a prominent position in the global market, and its clinical advantages have been widely recognized.
In 2023, the Chinese market also approved two drugs based on icosapent ethyl (IPE): in February, Guowei Pharmaceutical's “Liruixin®” was approved to reduce triglyceride levels in patients with severe hypertriglyceridemia; in June, “Weisipei” (Vascepa) was approved for marketing to reduce the risk of cardiovascular events in patients already treated with statins.
The purity and quality control of the drug are crucial in the development of EPA-EE. According to the Chinese Drug Registration Standard (JX20230052) and the United States Pharmacopeia (USP-NF 2024), both standards set specific requirements for the characteristics, identification, testing, assay, and impurity control of eicosapentaenoic acid ethyl ester, ensuring the purity, safety, and efficacy of the drug.
01 Impurity Detection and Identification
Impurity control of eicosapentaenoic acid ethyl ester (EPA-EE) covers the detection of various potential impurities, such as oxidation products (peroxide value, acid value, absorbance), non-target fatty acid ethyl esters, oligomers, and heavy metals.
The United States Pharmacopeia explicitly sets content requirements for total omega-3 acid ethyl esters in EPA-EE, and establishes limit standards for specific impurities (such as DHA-EE, AA-E, etc.). In addition, clear acceptance criteria are also set for heavy metal content, cholesterol content, and the content of ethyl esters other than omega-3 fatty acids.
The Chinese Drug Registration Standard focuses on the chromatographic retention time identification of eicosapentaenoic acid ethyl ester soft capsules and the quantitative analysis of specific impurities (such as ODTA-E, NDPA-E, AA-E, etc.). At the same time, specific requirements are also set for peroxide value, acid value limits, α-tocopherol content, and the content of specific impurities.
02 Quality Control
Quality control methods include high-performance liquid chromatography (HPLC) and gas chromatography (GC) to ensure accurate identification and quantification of impurities. These methods can ensure precise detection of the content and impurities of EPA-EE and other omega-3 fatty acid ethyl esters.
Precise control of impurities is not limited to common oxidation products and non-target fatty acid ethyl esters, but also includes heavy metals and other harmful substances. For example, the United States Pharmacopeia (USP-NF 2024) standard sets limit requirements for toxic impurities such as dioxins, furans, and polychlorinated biphenyls in omega-3 fatty acid ethyl esters, and uses US EPA Methods 1613 and 1668 for analysis to ensure the highest safety standards for the formulation.
The production of eicosapentaenoic acid ethyl ester (EPA-EE) faces high technical barriers, including raw material selection, extraction and purification technology, and strict control of impurities. As unsaturated fatty acids, EPA and DHA have very similar molecular structures and boiling points, making them difficult to separate and purify. To produce such high-purity EPA-EE API, it is necessary to overcome the key technology of high-purity pharmaceutical fish oil and master fish oil separation technology. In addition, control of various potential impurities during production also needs to be considered to ensure the quality and safety of the API.
To establish and improve the quality standards of eicosapentaenoic acid ethyl ester soft capsules, it is necessary to conduct systematic research on eicosapentaenoic acid ethyl ester (EPA-EE) and its impurity reference standards. Formulating and improving the standard reference standards for EPA-EE and its impurities, as well as detailed analytical method research, is the key to ensuring drug quality. This is of great significance for the new drug development and quality control of eicosapentaenoic acid ethyl ester, and will also promote the greater clinical application value of EPA-EE.
CATO has launched a full set of eicosapentaenoic acid ethyl ester (EPA-EE) impurity reference standards, with in-stock inventory. This will provide pharmaceutical companies and research institutions with more convenient impurity detection and quality control methods, helping to accelerate the development of EPA-EE-related drugs and improve drug quality.
